CNSY
Cerenome, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Cerenome, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
—
13F top-10 QoQ
Top fund weight
0.00%
CNSY weight · VTI
No changes.
No changes.
No peers for Cerenome, Inc. yet.
No peers for Cerenome, Inc. yet.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Cerenome, Inc.
1.72
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
—
—
−92.69%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.3M | 48.37% | −87.44% |
| BlackRockindex-like | $419,446 | 15.23% | −94.60% |
| Geodeindex-like | $332,941 | 12.09% | −96.22% |
| Vanguard Fiduciary Trustindex-like | $161,113 | 5.85% | −96.83% |
| Ashton Thomas Private Wealth | $149,917 | 5.44% | +4.23% |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $1.3M | 48.37% | −87.44% |
| BlackRockindex-like | $419,446 | 15.23% | −94.60% |
| Geodeindex-like | $332,941 | 12.09% | −96.22% |
| Vanguard Fiduciary Trustindex-like | $161,113 | 5.85% | −96.83% |
| Ashton Thomas Private Wealth | $149,917 | 5.44% | +4.23% |
Expected move
No implied move.